DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1473)

Multiple Myeloma | Emerging Therapies | Darzalex/Empliciti Launch Tracking Wave 3 (US)

Multiple Myeloma | Emerging Therapies | Darzalex/Empliciti Launch Tracking Wave 3 (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

This three-wave syndicated report series tracks the introduction of Darzalex, a human anti-CD38 MAb, and Empliciti, a humanized anti-SLAMF7 MAb. The FDA approved these agents in November 2015 for relapsed/refractory multiple myeloma. This series is based on primary research data collected at one month, three months, and one year after commercial availability of Darzalex and Empliciti. Along with awareness and sources of familiarity, the report assesses hematological oncologists’ trial, adoption, and use of these agents, including anticipated future trends. The analysis provides information on product perception, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Johnson & Johnson/Janssen’s and Bristol-Myers Squibb’s promotional efforts, and benchmarking against other recently launched oncology ;

  • Pub Date: March 2017
  • Author(s): Izabela Ammermann, PhD

Request report

Related reports:
You may also be interested in: